Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anecortave acetate in wet AMD following PDT
NCT00346866Phase 2Completed
- Sponsor
- Alcon Inc.
- Start
- May 2000
- Primary completion
- Dec 2001
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of anecortave in exudative macular degeneration (3 arms), sponsored by Alcon Inc. Primary endpoint: Mean change from baseline in logMAR visual acuity score at 6 months. Started May 2000; status: completed.
02
Drugs
anecortave
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on NCT00346866.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00346866.